Teva Pharmaceutical Indus Q3 Adjusted EPS $0.60 Misses $0.61 Estimate, Sales $3.85B Beat $3.72B Estimate
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Indus (NYSE:TEVA) reported Q3 earnings of $0.60 per share, missing the analyst consensus estimate of $0.61 by 1.64%. However, the company's quarterly sales of $3.85 billion beat the analyst consensus estimate of $3.72 billion by 3.49%. This represents a 7.09% increase over sales from the same period last year.
November 08, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Teva Pharmaceutical's Q3 earnings per share missed estimates, but sales exceeded expectations. This mixed result could lead to uncertain market reactions.
Teva's earnings miss could negatively impact the stock, but the sales beat could offset this. The net effect on the stock price is uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100